Background: Abrupt discontinuation of benzodiazepines often results in side effects including anxiety and insomnia, which can be barriers to discontinuation among long-term users. Melatonin improves the onset, duration, and quality of sleep. By preventing insomnia in those attempting to discontinue benzodiazepines, melatonin may facilitate benzodiazepine discontinuation.
Objectives: The primary objective was to determine the effect of melatonin compared with placebo on benzodiazepine discontinuation in adults attempting to discontinue benzodiazepines. The secondary objective was to determine the effect of melatonin on sleep quality in this population.
Methods: We searched PubMed, MEDLINE, EMBASE, PsychINFO, and ClinicalTrials.gov from inception to November 2014. We included randomized controlled trials published in English comparing melatonin with placebo that reported benzodiazepine discontinuation or sleep quality. Two reviewers independently screened trials, extracted data, and assessed the risk of bias.
Results: We included six trials randomizing 322 participants. The mean age of participants was approximately 64 years. The trials used varied tapering strategies to discontinue benzodiazepines over 4-10 weeks while using melatonin. Melatonin had no effect on the odds of successfully discontinuing benzodiazepines (odds ratio 0.72, 95% confidence interval 0.21-2.41, p = 0.59). There was important heterogeneity among the trials (I (2) = 76%). The effect of melatonin on sleep quality was inconsistent.
Conclusions: Melatonin had no effect on benzodiazepine discontinuation while the effect of melatonin on sleep quality was inconsistent. We cannot rule out a role of melatonin in improving benzodiazepine discontinuation or sleep quality owing to imprecise effect estimates. Larger, well-designed, and reported randomized controlled trials may provide more valid and precise estimates of the effect of melatonin on these outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40266-015-0322-5 | DOI Listing |
Itching tends to worsen at night in patients with itchy skin diseases, such as atopic dermatitis. Unconscious scratching during sleep can exacerbate symptoms, cause sleep disturbances, or reduce quality of life. Therefore, evaluating nocturnal scratching behaviour is important for better patient care.
View Article and Find Full Text PDFJ Prev Alzheimers Dis
February 2025
Department of Epidemiology and Data Science, Amsterdam UMC, VU University Medical Center, Amsterdam Public Health Research Institute, De Boelelaan 1118, Amsterdam 1081 HZ, The Netherlands.
Background: Few studies have addressed the association of sleep disturbances with incident dementia with long lag times. We add to this literature by investigating how lag times varying from 2.2 to 23.
View Article and Find Full Text PDFJ Affect Disord
January 2025
Department for Clinical Psychology and Psychotherapy, University of Freiburg, Germany. Electronic address:
Background: Increased emotional reactivity to stress, emotional dysregulation and sleep disturbances are interdependent trans-diagnostic processes that are present in internalising disorders such as depression and anxiety disorders. This study investigated which objective and subjective parameters of stress reactivity, sleep and emotional processing would predict symptoms of anxiety and depression in adolescents and young adults.
Methods: Participants were adolescents and young adults between the ages of 14 to 21 (N = 106, 25[24 %] male, M age = 17.
Environ Res
January 2025
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Background: Air pollution has been linked to respiratory diseases, while the effects of greenness remain inconclusive.
Objective: We investigated the associations between exposure to particulate matter (PM and PM), black carbon (BC), nitrogen dioxide (NO), ozone (O), and greenness (normalized difference vegetation index, NDVI) with respiratory emergency room visits and hospitalizations across seven Northern European centers in the European Community Respiratory Health Survey (ECRHS) study.
Methods: We used modified mixed-effects Poisson regression to analyze associations of exposure in 1990, 2000 and mean exposure 1990-2000 with respiratory outcomes recorded duing ECRHS phases II and III.
Dermatol Ther (Heidelb)
January 2025
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", "Sapienza" University of Rome, Polo Pontino, 04100, Latina, Italy.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact of tralokinumab, a humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD in a real-world setting, with a focus on different AD phenotypes.
Methods: An observational cohort of 30 adults treated with tralokinumab for ≥ 16 weeks was analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!